Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

When is the best time to zap brain tumors? new trial tests before, during, or after surgery

NCT ID NCT05871307

Disease control Sponsor: University Hospital Heidelberg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial looks at the best time to give radiotherapy for brain metastases that can be surgically removed. It compares giving radiation before surgery, during surgery, or after surgery. The goal is to see which timing best prevents the tumor from coming back. About 90 adults with solid tumors that have spread to the brain will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy (stereotactic radiosurgery or intraoperative radiation)
What this could lead to
If successful, this trial could identify the best timing for radiotherapy to improve local tumor control and reduce recurrence after brain metastasis surgery.
What could go wrong
This is a small, early-phase (phase II) exploratory trial with only 90 participants, so results may not be definitive or widely applicable. Different timings carry varying risks of radiation side effects or surgical complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed solid malignancy * Metastatic brain disease (1-10 brain metastases), with at least one brain metastasis in a non-eloquent location (i.e. motor or speech) planned for resection * Maximum size of the brain metastasis \<5cm * Eligibility of patients for both stereotactic radiotherapy and resection * Time interval from resection to adjuvant stereotactic radiosurgery of 2-6 weeks * Time interval from neoadjuvant stereotactic radiosurgery to resection of 1-7 days * Possibility to postpone resection for neoadjuvant stereotactic radiosurgery, if applicable * Karnofsky performance scores \>= 70 or Eastern Cooperative Oncology Group (ECOG) \>= 2 at enrollment * Age ≥ 18 years of age * For women with childbearing potential, (and men) adequate contraception. * Ability of subject to understand character and individual consequences of the clinical trial * Written informed consent (must be available before enrolment in the trial) Exclusion Criteria: Necessity of immediate surgical resection due to life threatening symptoms * brain metastasis directly located (≤10mm) next to the optic system or brain stem * Refusal of the patients to take part in the study * Small-cell lung cancer (SCLC) or hematologic malignancy as primary malignant illness * Leptomeningeal disease suspected RadCav Trial Protocol Version 1.1, 01.07.2022 18 * Previous radiotherapy of the brain * Contraindication for contrast-enhanced MRI * Pregnant or lactating women * Participation in another competing clinical study or observation period of competing trials, respectively

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases Radiotherapy

Contacts and locations

Locations

  • Department of Radiotherapy, University of Heidelberg

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.